Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Active PRA-216 for Atopic Dermatitis (AD)

This study will measure the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to dummy treatment (placebo) in patients with moderate to severe Atopic Dermatitis (AD)

Official registry: https://clinicaltrials.gov/study/NCT07810777 · Prana Therapies Inc · enrollment listed as 39

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Active PRA-216, or Placebo. The registry lists allocation as randomized. This study will measure the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to dummy treatment (placebo) in patients with moderate to severe Atopic Dermatitis (AD)

They plan to enroll about 39 people at 9 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis

Interventions: Active PRA-216, Placebo

Primary outcome (registry wording): Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 70 Years
  • Must be in good health with no significant medical history
  • Willing and able to attend all study visits, comply with study requirements
  • Documented AD diagnosis prior to enrollment
  • History of inadequate response to topical medications for AD

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

9 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Studies of Skin Microbes in Healthy People and in People With Skin Conditions

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.

NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07810777 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07810777?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07810777?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary